SEC. ___. FACILITATING EXCHANGE OF INFORMATION PRIOR TO APPROVAL.

Section 502(a) of the Federal Food, Drug, and Cosmet- 

etic Act (21 U.S.C. 352(a)) is amended—

(1) in paragraph (1)—

(A) by striking “formulary committee” and 

inserting “formulary or technology review com- 

mittee”;

(B) by striking “drugs for coverage” and 

inserting “drugs or devices for coverage”;

(C) by striking “approved under section 

505 or under section 351(a) of the Public 

Health Service Act for such drug” and insert- 

ing “approved, cleared, or licensed pursuant to 

section 505, 510(k), 513, or 515 of this Act or 

pursuant to section 351 of the Public Health 

Service Act for such drug or device”;

(D) by striking “approved for the drug 

under section 505 or under section 351 of the 

Public Health Service Act” and inserting “ap- 

proved for the drug or device pursuant to sec- 

tion 505, 510(k), 513, or 515 of this Act or 

pursuant to section 351 of the Public Health 

Service Act”; and
(E) by striking “The requirements set forth in section 505(a) or in subsections (a) and (k) of section 351 of the Public Health Service Act” and inserting “The requirements set forth in section 505(a), 510(k), 513, or 515 of this Act or section 351 of the Public Health Service Act”;

(2) by redesignating subparagraph (2) as subparagraph (3);

(3) by inserting after subparagraph (1) the following:

“(2)(A) Health care economic information or scientific information provided to a payor, formulary or technology review committee, or other similar entity with knowledge and expertise in the area of health care economic analysis carrying out its responsibilities for the selection of drugs or devices for coverage, reimbursement, or other population-based health care management, shall not be considered false or misleading or any other form of misbranding under this paragraph, or a violation of section 505, 510(k), 513, or 515 of this Act or section 351 of the Public Health Service Act, if it is based on competent and reliable scientific evidence and relates to an investigational use of a drug or device.
“(B) In order for information relating to an investigational use of an approved, cleared, or licensed drug or device to be provided pursuant to this subparagraph—

“(i) the study or studies the sponsor anticipates could be sufficient to support the approval, clearance, or licensing of such use must have been conducted;

“(ii) the sponsor must intend that a supplemental application will be submitted to the Secretary for approval, clearance, or licensing of the use; and

“(iii) the information must include, where applicable, a conspicuous and prominent statement describing any material differences between the information provided and the labeling approved pursuant to section 505, 510(k), 513, or 515 of this Act or pursuant to section 351 of the Public Health Service Act.

“(C) For purposes of this subparagraph, scientific information includes clinical and pre-clinical data and results relating to a product or use that has not been approved, cleared, or licensed and is being investigated or developed.”;

(4) in subparagraph (3), as redesignated—

(A) by striking “(A)”;

(B) by striking clause (B); and
(C) by striking “drug” each place it appears and inserting “drug or device”; and

(5) by adding at the end the following:

“(4) Nothing in this paragraph shall be construed to limit the ability of manufacturers or sponsors of drugs or devices to engage in communications or activities not specified in subparagraph (2) or (3) that are otherwise permissible.”.